Andrx Pharmaceuticals, LLC
Records under this name other than patents Andrx Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Andrx Pharmaceuticals, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,314,640 | Formulation and process for drug loaded cores Term ended Term ended Jul 6, 2025 · From the USPTO record | Term ended | Term ended Jul 6, 2025 | From the USPTO record |
| US 8,092,831 | Antihistamine and decongestant system Lapsed on the fee record Ended Jan 10, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 10, 2024 | From the USPTO record |
| US 7,988,993 | Oral controlled release dosage form Lapsed on the fee record Ended Aug 2, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 2, 2023 | From the USPTO record |
| US 7,931,915 | Extended release venlafaxine formulation Lapsed on the fee record Ended Apr 26, 2023 · From the USPTO record | Lapsed on the fee record | Ended Apr 26, 2023 | From the USPTO record |
| US 6,893,660 | Stable pharmaceutical compositions without a stabilizer Term ended Term ended Dec 22, 2022 · From the USPTO record | Term ended | Term ended Dec 22, 2022 | From the USPTO record |
| US 7,790,200 | Formulation and process for drug loaded cores Lapsed on the fee record Ended Sep 7, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 7, 2022 | From the USPTO record |
| US 8,668,932 | Extended release venlafaxine formulation Lapsed on the fee record Ended Mar 11, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 11, 2022 | From the USPTO record |
| US 8,628,797 | Oral extended-release composition Lapsed on the fee record Ended Jan 14, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jan 14, 2022 | From the USPTO record |
| US 8,529,946 | Rapidly disintegrating antihistamine formulation Lapsed on the fee record Ended Sep 10, 2021 · From the USPTO record | Lapsed on the fee record | Ended Sep 10, 2021 | From the USPTO record |
| US 6,589,553 | Controlled release oral dosage form Term ended Term ended Aug 30, 2021 · From the USPTO record | Term ended | Term ended Aug 30, 2021 | From the USPTO record |